RxDoctor Payments Data

Wilinda Dalgleish, APRN

Psychiatric/Mental Health · Lake Charles, LANPI 1396089587

Payments from drug & device makers

$2,357in general payments, 2019–2025

Across 103 payments — averaging $22.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$533
  • AbbVie$460
  • Alkermes, Inc.$373
  • Teva Pharmaceuticals USA, Inc.$259
  • Indivior Inc.$213
  • Johnson & Johnson$167
  • plus $353 from 5 others

What the payments were for

  • Food & beverage$2,24595%
  • Education$1115%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,357 in reported general payments places this provider in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana

Medicare billing

Part B allowed, 2024
$11,536
Medicare patients
32
Services billed
135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate13$103,587
VraylarCariprazine Hcl37$55,238
RexultiBrexpiprazole12$20,136
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl52$12,739
BelsomraSuvorexant24$9,888
VyvanseLisdexamfetamine Dimesylate15$5,747
Olanzapine OdtOlanzapine13$1,299
Oxcarbazepine11$1,116
Memantine Hcl ErMemantine Hcl25$986
Quetiapine Fumarate104$946
Haloperidol Decanoate23$890
Aripiprazole52$813
Olanzapine79$728
Desvenlafaxine Succinate ErDesvenlafaxine Succinate15$718
Gabapentin65$692

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$134$103,58713 claims
AbbVieVraylar$460$55,23837 claims
Otsuka America Pharmaceutical, Inc.Rexulti$130$20,13612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →